Andera Partners

PARIS, null · Quarter end: Sep 30, 2026 · Filed with SEC: Oct 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$175.7M2026 Q3
Positions7
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.100.0%

Andera Partners reported 7 positions worth $175.7M as of September 30, 2026 (13F filed October 16, 2026). Largest holding: KMTS (43.9%).

7 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 KMTSKestra Medical Technologies$77.2M43.94%2,728,679——+1.2%
▸ 2 MLYSMineralys Therapeutics$40.0M22.77%1,591,917——-39.0%
▸ 3 AVLNAvalyn Pharma$26.5M15.08%929,824——+6.3%
▸ 4 AGMBAgomAb Therapeutics$17.1M9.72%1,538,702——-42.7%
▸ 5 IVAInventiva S.A.$13.4M7.63%3,633,181———
▸ 6 EVMNEvommune$804.2K0.46%97,362——-7.6%
▸ 7 NYXHNyxoah$720.4K0.41%522,057———

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does Andera Partners hold as of Q3 2026?

Andera Partners reported 7 positions worth $175.7M in its Q3 2026 13F filing. Largest positions: KMTS (43.9%), MLYS (22.8%), AVLN (15.1%), AGMB (9.7%) and IVA (7.6%).

What did Andera Partners buy in Q3 2026?

No previous quarter is available yet; the comparison appears with the next filing.

What did Andera Partners sell in Q3 2026?

No previous quarter is available yet.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.